- Home
- PPCB vs MTNB Comparison
PPCB vs MTNB Comparison
Compare PPCB & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPCB | MTNB |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.6M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PPCB | MTNB |
|---|---|---|
| Price | $0.32 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 213.1K | 174.2K |
| Earning Date | 11-16-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.15 |
| 52 Week High | $6.79 | $3.16 |
Technical Indicators
Market Signals| Indicator | PPCB | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 25.33 | 54.71 |
| Support Level | $0.17 | $0.56 |
| Resistance Level | $0.40 | $3.16 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 2.01 | 4.74 |
Price Performance
Historical ComparisonAbout PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.